

Expected date of quarterly report submission:	February 13, 2013
Expected date of dividend payment commencement:	-
Preparation of quarterly supplementary explanatory material:	Yes
Quarterly results briefing held:	Yes

(Figures are rounded down to the nearest million yen unless otherwise stated.)

1. Consolidated Financial Results for the Third Quarter of Fiscal 2012 (April 1, 2012 to December 31, 2012)

(1) Consolidated Operating Results (cumulative)

(Percentage figures show year-on-year change.)

	Net sales		Operating income		Ordinary income		Net income	
	(¥ million)	%	(¥ million)	%	(¥ million)	%	(¥ million)	%
3Q Fiscal 2012	431,553	(14.5)	54,125	(34.2)	50,224	(35.5)	34,011	(30.9)
3Q Fiscal 2011	504,800	(17.8)	82,215	(24.9)	77,897	(24.2)	49,191	(27.0)

(Note) Comprehensive income: 3Q Fiscal 2012 ¥51,112 million [109.6%] 3Q Fiscal 2011 ¥24,383 million [2.1%]

	Basic earnings per share	Diluted earnings per share
	(¥)	(¥)
3Q Fiscal 2012	119.34	119.31
3Q Fiscal 2011	172.62	172.61

(2) Consolidated Financial Positions

	Total assets	Equity	Shareholders' equity ratio	Shareholders' equity per share
	(¥ million)	(¥ million)	%	(¥)
As of December 31, 2012	968,245	429,984	43.9	1,491.73
As of March 31, 2012	1,004,660	423,427	41.5	1,462.53

(Reference) Shareholders' equity

As of December 31, 2012 ¥425,168 million As of March 31, 2012 ¥416,793 million

Supplementary Materials

Table of Contents

(Page)

1. Qualitative Information Concerning Consolidated Financial Results (April 1, 2012 to December 31, 2012)	
1) Qualitative Information Concerning Consolidated Operating Results (April 1, 2012 to December 31, 2012)	2
2) Research & Development Pipeline, Alliances, and Other Events	5
3) Qualitative Information Concerning Consolidated Financial Position	10
4) Profit Appropriation Basic Policy and Dividend Forecast for the End of Fiscal 2012	11
5) Qualitative Information Concerning Consolidated Financial Forecasts for Fiscal 2012 (April 1, 2012 to March 31, 2013)	12
2. Explanatory Notes in Financial Results Summary	
1) Changes in Number of Significant Subsidiaries During the Period	13
2) Application of Special Accounting Treatment in Preparation of Consolidated Quarterly Financial Statements	13
3) Changes in Accounting Policies, Accounting Estimates and Restatements	13
3. Consolidated Financial Statements	
1) Consolidated Balance Sheets	14
2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	16
3) Consolidated Statements of Cash Flows	18
4) Going Concern	19
5) Note Regarding Significant Changes in the Amount of Shareholders' Equity	19
6) Segment Information	19
7) Significant Subsequent Events	21

- 1. Qualitative Information Concerning Consolidated Financial Results (April 1, 2012 to December 31, 2012)**
- 1) Qualitative Information Concerning Consolidated Operating Results (April 1, 2012 to December 31, 2012)**

[Sales and Income]

Net income was ¥34,011 million; depreciation of property, plant and equipment and amortization of intangible assets was ¥31,713 million; amortization of goodwill was ¥5,657 million; and loss on impairment of long-lived assets (including loss on devaluation of investment securities) was ¥1,506 million.

As a result, cash income was ¥72,889 million (down 14.9% year on year), with cash income per share of ¥255.76 (down ¥44.88 per share from the same period of the previous fiscal year).

[Performance by Segment]

(Net sales for each segment include net sales to external customers only.)

The Group's segments comprise the Pharmaceuticals and Other businesses, with the Pharmaceuticals Business of each geographical region being identified as a reporting segment. Effective from the fiscal year ending March 31, 2013, the Group has designated four new reporting segments as follows: East Asia (Japan, China, South Korea, Taiwan and Hong Kong); Americas (North, Central and South America); EMEA (Europe, the Middle East and Africa) and Indo-Pacific (South Asia, ASEAN countries and Oceania). In line with these changes, figures contained in this report for the fiscal year ended March 31, 2012 are based on the new reporting segments.

East Asia Pharmaceuticals Business

a result, assumed sole promotion on January 1, 2013.

Americas Pharmaceuticals Business

Net sales totaled ¥114,460 million (down 4.5% year on year; down 5.6% year on year excluding the impact of the exchange rate), with segment profit of ¥25,689 million (up 4.1% year on year).

Sales of Aciphex came to ¥37,820 million (down 11.9% year on year), sales of Aricept came to ¥9,339 million (down 0.8% year on year), wh

2) Research & Development Pipeline, Alliances, and Other Events

[Status of Ongoing Research & Development Pipelines]

The anticancer agent Halaven (eribulin mesylate) obtained approval as a treatment for breast cancer sequentially around the world and, as of January 2013, the agent is approved

to extend the use of the antiepileptic agent Zonegran (zonisamide) as monotherapy for the treatment of partial-onset seizures in adults with newly diagnosed epilepsy. Zonegran was also approved in Russia as an adjunctive therapy in the treatment of adult epilepsy patients with partial-onset seizures.

In June 2012, the anti-rheumatic agent Careram (iguratimod) was approved for the treatment of RA.

In May 2012, the Company submitted a marketing authorization application seeking approval in Japan for two types of new triple formulation packs (combination packs) for *Helicobacter pylori* eradication that include its proton pump inhibitor Pariet (rabeprazole sodium) as well as amoxicillin hydrate and either clarithromycin for primary eradication or metronidazole for secondary eradication. In August 2012, the Company submitted a public knowledge-based application seeking approval in Japan for *Helicobacter pylori* gastritis as an additional indication for *Helicobacter pylori* eradication by concomitant therapy that includes amoxicillin hydrate and either clarithromycin or metronidazole.

In June 2012, an application seeking approval to market the antiepileptic agent Zonegran for the treatment of partial-onset seizures in pediatric patients with epilepsy age six years and older was accepted for review in the EU.

In August 2012, the Company submitted a marketing authorization application for the antiepileptic agent E2080 (rufinamide) in Japan seeking approval to market the agent as an adjunctive therapy in the treatment of LGS.

In November 2012, the U.S. FDA accepted for review Eisai's New Drug Application (NDA)

aiming for submission of applications in the U.S., Europe and Asia including Japan and China. A new Phase II study of the agent for non-small cell lung cancer was initiated in the United States, Europe and Asia including Japan.

A Phase II study to investigate an anti-Alzheimer's disease agent BAN2401 (a humanized

[Cash Flows]

Net cash provided by operating activities amounted to ¥53,465 million (down ¥1,384 million from the same period of the previous fiscal year). More specifically, income before income taxes and minority interests was ¥51,531 million; depreciation and amortization was ¥31,713 million; and income taxes paid decreased by ¥12,419 million to ¥24,671 million from the same period of the previous fiscal year.

Net cash provided by investing activities amounted to ¥20,943 million (up ¥10,776 million from the same period of the previous fiscal year). Net decrease in time deposits (exceeding three months) came to ¥29,063 million.

Net cash used in financing activities amounted to ¥60,832 million (up ¥4,154 million from the same period of the previous fiscal year). This was mainly due to repayment of long-term borrowings amounting to ¥40,000 million and cash dividends paid totaling ¥42,748 million.

As a result, cash and cash equivalents as of the end of this period stood at ¥133,290 million (up ¥20,722 million from the end of the previous fiscal year).

4) Profit Appropriation Basic Policy and Dividend Forecast for the End of Fiscal 2012

The Company is devoted to providing sustainable and stable dividends based on its consolidated financial performance along with the dividend-on-equity ratio (DOE) and cash income.

DOE encompasses both the dividend payout ratio (DPR), which measures the extent to which profits are distributed to shareholders in the form of dividends, and return on equity (ROE), which measures how effectively the Company uses the money invested by shareholders to generate profits.

Cash income expresses the Company's ability to generate cash. Cash income is used for shareholder return, investment in future growth and repayment of borrowings and other operations to improve the financial standing of the Company. Eisai is committed to prioritizing stable dividend payments and investment in future growth, and considers it important to allocate cash income appropriately and flexibly according to changes in financial conditions.

From this standpoint, the Company considers it well-balanced and appropriate to take DOE and cash income, in addition to consolidated financial results, into consideration in a comprehensive manner in mid-term assessments of shareholder return. In addition, acquisition of treasury stock will

5) Qualitative Information Concerning Consolidated Financial Forecasts for Fiscal 2012

(April 1, 2012 to March 31, 2013)

[Consolidated Forecasts]

The full fiscal year consolidated forecasts have been revised as follows from the forecasts previously announced in May 2012, in light of the consolidated financial results for the quarter ended December 31, 2012.

	Revised forecast		Previous forecast		Increase/ Decrease	Rate of change (%)
	(A)	(%)	(B)	(%)	(A-B)	
Net sales	¥573,500 mil.	(11.5%)	¥610,000 mil.	(5.9%)	(¥36,500 mil.)	(6.0%)
Operating income	¥71,500 mil.	(25.3%)	¥87,000 mil.	(9.1%)	(¥15,500 mil.)	(17.8%)
Ordinary income	¥66,500 mil.	(26.1%)	¥82,000 mil.	(8.9%)	(¥15,500 mil.)	(18.9%)
Net income	¥47,000 mil.	(19.7%)	¥59,000 mil.	0.8%	(¥12,000 mil.)	(20.3%)

Notes: *Forecasted annual earnings per share (full year): ¥164.91

3. Consolidated Financial Statements

1) Consolidated Balance Sheets

(millions of yen)

	March 31, 2012	December 31, 2012
Assets		
Current assets		
Cash and cash in banks	104,444	70,028
Notes and accounts receivable—trade	197,166	180,263
Short-term investments	83,737	110,331
Merchandise and finished goods	43,108	51,841
Work-in-process	18,283	18,921
Raw materials and supplies	13,804	14,642
Deferred tax assets	42,479	42,659
Other	22,974	22,463
Allowance for doubtful receivables	(163)	(134)
Total current assets	525,835	511,018
Non-current assets		
Property, plant and equipment		
Buildings and structures net	85,580	83,884
Other net	57,998	55,182
Total property, plant and equipment	143,578	139,067
Intangible assets		
Goodwill	119,054	119,282
Sales rights	65,338	55,286
Core technology	40,492	41,003
Other	13,755	12,841
Total intangible assets	238,640	228,414
Investments and other assets		
Investment securities	39,079	37,894
Deferred tax assets	45,101	45,723
Other	12,586	6,280
Allowance for doubtful accounts	(163)	(152)
Total investments and other assets	96,605	89,745
Total non-current assets	478,824	457,226
Total assets	1,004,660	968,245

(Consolidated Statements of Comprehensive Income)

(millions of yen)

	April 1, 2011– December 31, 2011	April 1, 2012– December 31, 2012
Income before minority interests	49,474	34,230
Other comprehensive income (loss)		
Valuation difference on available-for-sale securities	(2,351)	(418)
Deferred gain (loss) on derivatives under hedge accounting	(310)	(9)
Foreign currency translation adjustments	(22,429)	17,310
Total other comprehensive income (loss)	(25,091)	16,882
Comprehensive Income (loss)	24,383	51,112
(Breakdown)		
Comprehensive income (loss) attributable to shareholders of the parent company	24,360	51,016
Comprehensive income (loss) attributable to minority interests	22	96

3) Consolidated Statements of Cash Flows

(millions of yen)

	April 1, 2011– December 31, 2011	April 1, 2012– December 31, 2012
Operating activities		
Income before income taxes and minority interests	80,001	51,531
Depreciation and amortization	30,915	31,713
Amortization of goodwill	5,357	5,657
Gain on negative goodwill	-	(1,960)
Other loss (gain)	1,807	4,365
Decrease (increase) in notes and accounts receivable—trade	(22,636)	19,275
Decrease (increase) in inventories	(3,315)	(8,264)
Increase (decrease) in trade payables	3,360	(2,197)
Increase (decrease) in other current liabilities	(5,229)	(18,789)
Increase (decrease) in reserve for sales rebates	(7,595)	(2,873)
Other	12,952	3,245
Sub-total	95,618	81,703
Interest and dividends received	1,398	1,277
Interest paid	(5,075)	(4,842)
Income taxes paid	(37,090)	(24,671)

- (3) Information concerning loss on impairment of long-lived assets and goodwill by reporting segment
Not applicable

II. Third quarter of this fiscal year (April 1, 2012 to December 31, 2012)

- (1) Information concerning sales and profit (loss) by reporting segment

(millions of yen)

	Reporting Segment ¹					Other ²	Total
	Pharmaceuticals Business						
	East Asia	Americas	EMEA	Indo-Pacific	Sub-total		
Net sales to external customers	274,628	114,460	18,876	5,100	413,065	18,487	431,553

2012.12

Thi — arter Ende  1 2012

1. Consolidated Financial Highlights	-----	1
2. Consolidated Statements of Income	-----	3
3. Consolidated Statements of Cash Flows	-----	5
4. Financial Results by Business Segment	-----	6

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

	Nine months ended Dec. 31			Full year
	FY2011	FY2012	Diff.	FY2011
Capital expenditures	11.7	15.0	3.2	20.7
Property, plant and equipment	7.1	5.1	(2.0)	12.7
Intangible assets	4.7	9.9	5.2	8.0
Depreciation and amortization	30.9	31.7	0.8	41.7

* "Depreciation and amortization" includes amortization of "Intangible assets."

5) Financial Results by Business Segment

(1) Consolidated Net Sales by Reporting Segment

(billions of yen)

	Nine months ended Dec. 31			Full year
	FY2011	FY2012	YOY %	FY2011
East Asia pharmaceuticals business	315.7	274.6	87.0	400.4
Japan pharmaceuticals business	294.3	250.0	85.0	372.6
Americas pharmaceuticals business	119.8	114.5	95.5	157.5
U.S. pharmaceuticals business	119.8	114.2	95.4	157.4
EMEA pharmaceuticals business	34.0	18.9	55.5	42.7
Indo-Pacific pharmaceuticals business	5.1	5.1	100.0	6.7
Other	30.2	18.5	61.3	40.7
Consolidated net sales	504.8	431.6	85.5	648.0

* Net sales to external customers for each segment.

(2) Consolidated Operating Income by Reporting Segment

(billions of yen)

	Nine months ended Dec. 31		
	FY2011	FY2012	YOY %
East Asia pharmaceuticals business	136.2	111.0	81.6
Japan pharmaceuticals business	131.9	106.2	80.5
Americas pharmaceuticals business	24.7	25.7	104.1
EMEA pharmaceuticals business	5.2	1.3	24.9
Indo-Pacific pharmaceuticals business	1.4	1.2	90.4
Other	14.8	9.2	61.9
R&D expenses	93.9	87.2	92.9
Non-allocated SG&A expenses	6.1	7.1	115.0
Consolidated Operating income	82.2	54.1	65.8

* The Group's segments comprise the pharmaceuticals and other businesses, with the pharmaceuticals business of each region being identified as a reporting segment.

* The Eisai Group's pharmaceuticals business is classified into segments comprising East Asia (Japan, China, South Korea, Taiwan and Hong Kong), the Americas (North, Central and South America), EMEA (Europe, the Middle East and Africa) and the Indo-Pacific (South Asia, ASEAN countries and Oceania), with steps being taken to develop and implement strategies tailored to the specific characteristics of each region or market.

In the pharmaceuticals business, the Group is primarily engaged in the manufacture and sale of prescription drugs.

R&D expenses have not been allocated to any segment as the Group manages such expenses on a global basis.

Similarly, Group headquarters management costs and other expenses have not been allocated to any segment as these are the costs covering Group-wide operations.

2. Consolidated Statements of Income

(billions of yen)

	FY2011	Sales %	FY2012	Sales %	YOY %	Diff. FY2011	Sales %
Net sales	504.8	100.0	431.6	100.0	85.5	(73.2)	648.0
Cost of sales	129.3	25.6	128.1	29.7	99.1	(1.2)	173.4
Gross profit	375.5	74.4	303.4	70.3	80.8	(72.1)	474.6
R&D expenses	93.9	18.6	87.2	20.2	92.9	(6.6)	125.1
SG&A expenses	199.4	39.5	162.0	37.5	81.3	(37.3)	253.7
Personnel expenses	57.6	11.4	50.8	11.8	88.2	(6.8)	74.5
Selling expenses	102.2	20.2	76.9	17.8	75.3	(25.3)	127.1
Administrative and other expenses	39.5	7.8	34.3	7.9	86.7	(5.3)	52.1
Operating income	82.2	16.3	54.1	12.5	65.8	(28.1)	95.7
Non-operating income	1.6	0.3	1.7	0.4		0.0	2.0
Non-operating expenses	6.0	1.2	5.6	1.3		(0.4)	7.7
Ordinary income	77.9	15.4	50.2	11.6	64.5	(27.7)	90.0
Special gain	2.4	0.5	2.9	0.7		0.5	6.3
Special loss	0.3	0.1	1.6	0.4		1.3	1.7
Income before income taxes and minority interests	80.0	15.8	51.5	11.9	64.4	(28.5)	94.6
Income taxes current	21.5	4.3	23.0	5.3		1.6	28.6
Income taxes							

Consolidated Statements of Comprehensive Income

	FY2011	FY2012	YOY %	Diff.	<u>Full year</u> FY2011
Income before minority interests	49.5	34.2	69.2	(15.2)	58.9
Other comprehensive income (loss)	(25.1)	16.9	-	42.0	(3.3)
Valuation difference on available-for-sale securities	(2.4)	(0.4)	-	1.9	1.1

3. Consolidated Statements of Cash Flows

	(billions of yen)		
	<u>Nine months ended Dec. 31</u>		
	FY2011	FY2012	Diff.
Income before income taxes and minority interests	80.0	51.5	(28.5)
Depreciation and amortization / Amortization of goodwill	36.3	37.4	1.1
Gain on negative goodwill	-	(2.0)	(2.0)
Decrease (increase) in notes and accounts receivable trade, trade payables and inventories	(22.6)	8.8	31.4
Increase (decrease) in accounts payable other / Accrued expenses, etc.	(5.2)	(18.8)	(13.6)
Other	7.2	4.7	(2.4)
[Sub-total]	95.6	81.7	(13.9)
Interest received (paid), etc.	(3.7)	(3.6)	0.1
Income taxes paid	(37.1)	(24.7)	12.4
Net cash provided by (used in) operating activities	54.9	53.5	(1.4)
Capital expenditures (cash basis)	(11.8)	(14.6)	(2.8)
Purchases of securities / Proceeds from sales and redemption of securities	15.1	0.4	(14.7)
Proceeds from sales of investment in consolidated subsidiaries in the previous fiscal year	-	6.1	6.1
Net increase (decrease) in time deposits exceeding three months	6.5	29.1	22.6
Other	0.4	(0.1)	(0.4)
Net cash provided by (used in) investing activities	10.2	20.9	10.8
Net increase (decrease) in short-term borrowings	27.0	(2.4)	(29.4)
Net increase (decrease) in commercial paper	-	25.0	25.0
Repayment of long-term borrowings	-	(40.0)	(40.0)
Redemptions of bonds and debentures	(40.0)	-	40.0
Dividends paid	(42.7)	(42.7)	(0.0)
Other net	(0.9)	(0.6)	0.3
Net cash provided by (used in) financing activities	(56.7)	(60.8)	(4.2)
Foreign currency translation adjustments on cash and cash equivalents	(6.2)	7.1	13.3
Net increase (decrease) in cash and cash equivalents	2.1	20.7	18.6
Cash and cash equivalents at the beginning of period	102.8	112.6	9.8
Cash and cash equivalents at the end of period	104.9	133.3	28.3
Free cash flow	43.1	38.9	(4.1)

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (cash basis)"

Notes

Net cash provided by (used in) operating activities

Decrease in income taxes paid due to an decrease in taxable income in the previous year

Net cash provided by (used in) investing activities

Increase from reversal of time deposits exceeding three months as the fund source for repayment of long-term borrowings

Net cash provided by (used in) financing activities

Cash dividends paid and repayment of long-term borrowings

4. Financial Results by Business Segment

1) East Asia Pharmaceuticals Business

(billions of yen)

(Japan, China, South Korea, Taiwan and Hong Kong)	Nine months ended Dec. 31			Full year
	FY2011	FY2012	YOY %	FY2011
Net sales	315.7	274.6	87.0 <86.8>	400.4
Segment profit	136.2	111.0	81.6	167.4

East Asia Net Sales Breakdown

Net sales in Japan	294.3	250.0	85.0	372.6
Prescription drugs	263.9	216.4	82.0	331.2
Consumer healthcare products, etc.	15.9	15.8	99.5	21.7
Generic drugs (Elmed Eisai Co., Ltd.)	10.1	13.5	133.7	13.7
Diagnostic products (EIDIA Co., Ltd.)	4.4	4.3	97.5	6.0

Japan prescription drugs - major products (Eisai)

Anti-Alzheimer's agent	91.2	56.0	61.4	108.3
Aricept				
Proton pump inhibitor	47.8	38.6	80.7	60.9
Pariet				
Peripheral neuropathy treatment	23.4	20.1	85.9	30.0
Methycobal				
Fully human anti-TNF- monoclonal antibody	15.4	18.1	118.0	20.5
Humira				
Pain treatment (peripheral neuropathic pain, fibromyalgia)	8.4	10.3	122.7	11.3
Lyrica (co-promotion income)				
Oral anticoagulant	7.6	7.7	101.9	9.9
Warfarin				
Osteoporosis treatment	8.8	6.9	78.8	11.0
Actonel				
Gastritis / gastric ulcer treatment	7.9	6.0	76.6	10.0
Selbex				
Anticancer agent	1.8	4.1	226.4	3.1
Halaven				

Japan consumer healthcare products - major product groups (Eisai)

Vitamin B2 preparation ("Chocola BB Plus," etc.)	8.5	8.6	101.1	11.3
Chocola BB Group				

Net sales in China

Billions JPY	13.0	15.8	122.0 <118.2>	16.9
--------------	------	------	------------------	------

China prescription drugs - major products

Peripheral neuropathy treatment	Billions JPY	5.7	6.8	118.5	7.5
Methycobal	[Millions RMB]	[465]	[534]	<114.8>	[605]
Liver disease / Allergic disease agents	Billions JPY	2.8	3.4	123.8	3.7
Stronger Neo-Minophagen C and Glycyron Tablets	[Millions RMB]	[226]	[271]	<119.9>	[303]
Anti-Alzheimer's agent	Billions JPY	1.3	1.6	124.5	1.6
Aricept	[Millions RMB]	[106]	[127]	<120.6>	[131]
Proton pump inhibitor	Billions JPY	0.8	1.0	125.4	1.2
Pariet	[Millions RMB]	[67]	[82]	<121.5>	[95]

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

2) Americas Pharmaceuticals Business (North, Central and South America)

		Nine months ended Dec. 31		
		FY2011	FY2012	YOY %
Net sales	Billions JPY	119.8	114.5	95.5 <94.4>
Segment profit	Billions JPY	24.7	25.7	104.1
Americas prescription drugs - major products				
Proton pump inhibitor Aciphex	Billions JPY [Millions USD]	42.9 [543]	37.8 [473]	88.1 <87.0>
Antiemetic agent Aloxi	Billions JPY	25.9	27.1	105.0 <103.7>
U.S. prescription drugs	Billions JPY [Millions USD]	25.9 [327]	27.1 [339]	105.0 <103.7>
DNA methylation inhibitor Dacogen	Billions JPY [Millions USD]	12.8 [162]	13.5 [169]	105.6 <104.3>
Anti-Alzheimer's agent Aricept	Billions JPY [Millions USD]	9.4 [119]	9.3 [117]	99.2 <98.0>
Anticancer agent Halaven	Billions JPY	7.9	8.5	108.7 <107.3>
U.S. prescription drugs	Billions JPY [Millions USD]	7.9 [99]	8.5 [106]	108.2 <106.9>
Injectable anticoagulant Fragmin	Billions JPY [Millions USD]	10.8 [137]	7.8 [97]	71.8 <70.9>

* Sales of Aricept 23 mg tablet out of total sales of Aricept for FY2012 (April 1, 2012 to December 31, 2012) totaled ¥4.5 billion (U.S.\$56 million).

* The U.S. is the only country where Eisai markets Aricept, Aciphex, Dacogen and Fragmin independently.

3) EMEA Pharmaceuticals Business (Europe, the Middle East and Africa)

		Nine months ended Dec. 31		
		FY2011	FY2012	YOY %
Net sales	Billions JPY	34.0	18.9	55.5 <59.3>
Segment profit	Billions JPY	5.2	1.3	24.9
EMEA prescription drugs - major products				
Anticancer agent Halaven	Billions JPY	1.2	3.6	315.9 <336.3>
Antiepileptic agent Zonegran	Billions JPY	3.4	3.4	98.6 <105.4>
Proton pump inhibitor Pariet	Billions JPY	4.1	2.4	59.2 <63.0>
Anti-Alzheimer's agent Aricept	Billions JPY	17.1	2.3	13.4 <14.5>

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

4) Indo-Pacific Pharmaceuticals Business (South Asia, ASEAN countries and Oceania)

		Nine months ended Dec. 31		
		FY2011	FY2012	YOY %
Net sales	Billions JPY	5.1	5.1	100.0 <102.1>
Segment profit	Billions JPY	1.4	1.2	90.4
Indo-Pacific prescription drugs - major products				
Anti-Alzheimer's agent Aricept	Billions JPY	1.3	1.3	98.7 <100.5>
Proton pump inhibitor Pariet	Billions JPY	1.3	1.2	95.6 <98.4>
Peripheral neuropathy treatment Methycobal	Billions JPY	0.6	0.7	111.6 <112.9>
Anticancer agent Halaven	Billions JPY	0.0	0.0	134.9 <132.4>

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

5) Sales of Major Products
(1) Oncology-Related Products

FY2011	FY2012	YOY %	<u>Full year</u> FY2011
--------	--------	----------	----------------------------

(3) Aciphex/Pariet (Proton pump inhibitor)

		Nine months ended Dec. 31			Full year
		FY2011	FY2012	YOY %	FY2011
Total	Billions JPY	98.2	82.1	83.6 <83.3>	126.4
East Asia	Billions JPY	49.9	40.6	81.4 <81.3>	63.6
Japan prescription drugs	Billions JPY	47.8	38.6	80.7	60.9
Americas	Billions JPY [Millions USD]	42.9 [543]	37.8 [473]	88.1 <87.0>	55.9 [707]
EMEA	Billions JPY	4.1	2.4	59.2 <63.0>	5.2
Indo-Pacific	Billions JPY	1.3	1.2	95.6 <98.4>	1.7

* The U.S. is the only country in the Americas where Eisai markets Aciphex independently.

(4) Humira (Fully human anti-TNF- monoclonal antibody)

		Nine months ended Dec. 31			Full year
		FY2011	FY2012	YOY %	FY2011
Total	Billions JPY	18.0	21.6	119.9 <119.9>	24.0
East Asia	Billions JPY	18.0	21.6	119.9 <119.9>	24.0
Japan prescription drugs	Billions JPY	15.4	18.1	118.0	20.5

6) Overseas Sales

(billions of yen)

	Nine months ended Dec. 31			Full year
	FY2011	FY2012	YOY %	FY2011
Overseas sales	198.6	172.0	86.6	258.3
Overseas sales (% of total sales)	39.3	39.9	-	39.9

* Net sales to external customers for each segment.

* Indices shown in parentheses "<>" compare data with the same period of the previous fiscal year on a constant currency basis.

5. Sales Forecasts by Reporting Segment (FY2012)

	(billions of yen)		
	Nine months ended Dec. 31	Full year	
	FY2012	FY2011	FY2012 est.
East Asia	274.6	400.4	<u>359.5</u>
Japan	250.0	372.6	<u>328.5</u>
Prescription drugs	216.4	331.2	<u>281.0</u>
Anti-Alzheimer's agent			
Aricept	56.0	108.3	<u>75.0</u>
Proton pump inhibitor			
Pariet	38.6	60.9	<u>50.0</u>
Peripheral neuropathy treatment			
Methycobal	20.1	30.0	<u>26.0</u>
Fully human anti-TNF- monoclonal antibody			
Humira	18.1	20.5	<u>24.0</u>
Oral anticoagulant			
Warfarin	7.7	9.9	10.0
Osteoporosis treatment			
Actonel	6.9	11.0	10.0
Anticancer agent			
Halaven	4.1	3.1	<u>6.0</u>
Consumer healthcare products, etc.	15.8	21.7	22.0
Vitamin B ₂ preparation ("Chocola BB Plus", etc.)			
Chocola BB Group	8.6	11.3	12.0
Generic drugs (Elmed Eisai Co., Ltd.)	13.5	13.7	19.0
Diagnostics (EIDIA Co., Ltd.)	4.3	6.0	6.5
China	15.8	16.9	<u>21.0</u>
Americas	114.5	157.5	<u>157.0</u>
U.S.	114.2	157.4	<u>156.0</u>
EMEA	18.9	42.7	<u>26.0</u>
Indo-Pacific	5.1	6.7	<u>7.5</u>
Other	18.5	40.7	<u>23.5</u>
Consolidated net sales	431.6	648.0	<u>573.5</u>

* Sales amounts by new reporting segments for FY2011 are provided for reference purposes only.

* FY2012 sales forecast for Aricept is ¥97.0 billion.

* FY2012 sales forecast for Pariet/Aciphex is ¥108.5 billion.

* FY2012 sales forecast for Halaven is ¥24.0 billion.

6. Consolidated Balance Sheets

1) Consolidated Balance Sheets <Assets>

	(billions of yen)					
	March 31,		Dec. 31,		YOY	Diff.
	2012	%	2012	%	%	
Total current assets	525.8	52.3	511.0	52.8	97.2	(14.8)
Cash and cash in banks	104.4		70.0			(34.4)
Notes and accounts receivable trade	197.2		180.3			(16.9)
Short-term investments	83.7		110.3			26.6
Inventories	75.2		85.4			10.2
Deferred tax assets	42.5		42.7			0.2
Other	23.0		22.5			(0.5)
Allowance for doubtful receivables	(0.2)		(0.1)			0.0
Total non-current assets	478.8	47.7	457.2	47.2	95.5	(21.6)
Total property, plant and equipment	143.6	14.3	139.1	14.4	96.9	(4.5)
Buildings and structures net	85.6		83.9			(1.7)
Other net	58.0		55.2			(2.8)
Total Intangible assets	238.6	23.8	228.4	23.6	95.7	(10.2)
Goodwill	119.1		119.3			0.2
Sales rights	65.3		55.3			(10.1)
Core technology	40.5		41.0			0.5
Other	13.8		12.8			(0.9)
Total investments and other assets	96.6	9.6	89.7	9.3	92.9	(6.9)
Investment securities	39.1		37.9			(1.2)
Deferred tax assets	45.1		45.7			0.6
Other	12.6		6.3			(6.3)
Allowance for doubtful receivables	(0.2)		(0.2)			0.0
Total assets	1,004.7	100.0	968.2	100.0	96.4	(36.4)

Notes

Total assets

Decrease in cash and cash in banks due to repayment of long-term borrowings of ¥40.0 billion

2) Consolidated Balance Sheets <Liabilities and Equity>

	March 31,		Dec. 31,		(billions of yen)	
	2012	%	2012	%	YOY	Diff.
					%	
Total current liabilities	207.9	20.7	231.3	23.9	111.2	23.3
Notes payable trade and accounts payable trade	26.2		24.3			(1.9)
Short-term borrowings	6.0		3.6			(2.4)
Long-term borrowings (current portion)	40.0		17.3			(22.7)
Commercial paper	-		25.0			25.0
Bonds and debentures (current portion)	-		50.0			50.0
Accounts payable other / Accrued expenses	97.6		81.9			(15.7)
Income tax payable	11.3		5.9			(5.4)
Reserve for sales rebates	16.5		14.2			(2.2)
Other	10.4		9.0			(1.4)
Total non-current liabilities	373.3	37.2	307.0	31.7	82.2	(66.3)
Bonds and debentures	80.0		30.0			(50.0)
Long-term borrowings	219.3		204.6			(14.7)
Deferred tax liabilities	23.0		18.8			(4.2)
Liability for retirement benefits	31.4		25.7			(5.7)
Other	19.6		27.8			8.2
Total liabilities	581.2	57.9	538.3	55.6	92.6	(43.0)
Total shareholders' equity	526.6	52.4	518.0	53.5	98.4	(8.6)
Common stock	45.0		45.0			-
Capital surplus	56.9		56.9			(0.0)
Retained earnings	464.2		455.4			(8.7)
Treasury stock	(39.4)		(39.3)			0.1

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

	FY2011				FY2012		
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter	2nd Quarter	3rd Quarter
Capital expenditures	2.7	4.2	4.8	9.0	7.0	4.4	3.6
Property, plant and equipment	1.8	2.7	2.6	5.6	1.3	2.2	1.5
Intangible assets	0.9	1.6	2.2	3.3	5.6	2.2	2.0
Depreciation and amortization	10.5	10.2	10.2	10.8	10.2	10.6	10.9

* "Depreciation and amortization" includes amortization of "Intangible assets."

(3) Aciphex/Pariet

1st
Quarter

8. Non-consolidated Financial Highlights

1) Non-consolidated Financial Highlights

(1) Income Statement Data

	(billions of yen)			
	<u>Nine months ended Dec. 31</u>		<u>Full Year</u>	
	<u>FY2011</u>	<u>FY2012</u>	<u>YOY</u>	<u>FY2011</u>
			%	
Net sales	322.4	264.0	81.9	408.2
Cost of sales	71.4	73.8	103.4	94.7
R&D expenses	87.1	82.1	94.3	116.3
SG&A expenses	102.0	81.0	79.4	130.3
Operating income	62.0	27.1	43.7	66.9
Ordinary income				

9 . Major News Releases

Date	Description
April 2012	<p>Eisai and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe, etc. <issued on April 2></p> <p>Eisai Diagnostics Subsidiary EIDIA Enters into Sales Agreements with Medical Equipment Manufacturers for PROTOCO2L Carbon Dioxide Insufflation System for CT Colonography <issued on April 3></p> <p>Eisai Enters into Partnership with PharmaSwiss for Halaven (eribulin) Promotion and Distribution in Central and Eastern European (CEE) Countries <issued on April 5></p> <p>Eisai to Launch Insomnia Treatment Lunesta in Japan <issued on April 17></p> <p>Eisai Amends License Agreement with Teikoku Pharma USA for Aricept Transdermal Patch System <issued on April 20></p> <p>Abbott Japan and Eisai Have Cleared the Condition for Approval of Humira, a Fully Human Anti-TNF-Monoclonal Antibody, for Plaque Psoriasis and Psoriasis Arthropica in Terms of the All-Case Surveillance <issued on April 23></p> <p>German Federal Regulator Confirms Additional Benefit of Anticancer Agent Halaven for Metastatic or Locally Advanced Breast Cancer <issued on April 23></p>
May	<p>Eisai's US Research Subsidiary H3 Biomedicine to Collaborate with UK-Based Horizon Discovery to Identify and Validate Novel, Patient-Relevant Cancer Targets <issued on May 2></p> <p>Anti-obesity Agent Lorcaserin Receives Positive Vote from FDA Advisory Committee <issued on May 11></p> <p>Eisai Inc. Expands Marketing and Supply Agreement with Arena for Antiobesity Agent Lorcaserin <issued on May 11></p> <p>Issuance of Stock Acquisition Rights for the Purpose of Granting Stock Options to the Company's Employees <issued on May 15></p> <p>Eisai to Present New Research on Oncology Product Portfolio and Pipeline at 48th ASCO Annual Meeting <issued on May 18></p> <p>Eisai Launches New Mobile Website to Support Reflux Esophagii48th8apor eTSdkMpit<02 a<MmT2cgfolio and Pipeline at 48th</p>

Date	Description
July 2012	European Commission Approves Eisai's AMPA Receptor Antagonist Fycompa (perampanel) <issued on July 27>

Date	Description
December	Phase III Study (Study 301) Results of Anticancer Agent Halaven Versus Capecitabine In Locally Advanced Or Metastatic Breast Cancer Presented At 2012 SABCS <issued on December 7>
	Eisai Receives Six-Month Pediatric Exclusivity for Proton-Pump Inhibitor Aciphex in the U.S. <issued on December 10>
	Scottish Medicines Consortium Approves AMPA Receptor Antagonist Fycompa As Antiepileptic Treatment Under National Health Service Scotland <issued on December 11>
	Eisai North Carolina Plant Enters into Strategic Manufacturing Alliance Agreement with U.S.'s Biogen Idec <issued on December 13>
	Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological Diseases <issued on December 14>
	U.S. Subsidiary Eisai Inc. Divests U.S. Rights for Antineoplastic Gliadel Wafer to Arbor Pharmaceuticals, Inc. <issued on December 18>
	Approval of A Once-Monthly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent in Japan <issued on December 25>
January 2013	Novartis Pharma and Eisai Terminate Co-Promotion Agreement for COPD Therapies <issued on January 7>
	Eisai Signs Agreement with Epizyme and Roche Molecular Systems to Develop Companion Diagnostic <issued on January 8>
	Nobel Pharma and Eisai Announce Japan Launch of Antineoplastic Agent Gliadel 7.7mg Implant <issued on January 8>
	Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer <issued on January 11>

E7040 (Transcatheter arterial embolization (TAE) of hypervascular tumors)		(JP) PIII	Oncology and supportive care
E7080 (Thyroid cancer)		(JP/US/EU/AS) PIII	Oncology and Supportive Care
E7080 (Hepatocellular carcinoma)		(JP/US/EU/CN/AS) PIII	Oncology and Supportive Care
MORAb-003 (Platinum-sensitive ovarian cancer)		(JP/US/EU/AS) PIII	Oncology and Supportive Care
Fycompa (Generalized seizures)	AI	(JP/US/EU/AS) PIII	Neurology
Halaven (Second-line treatment for breast cancer)	AI	(US/EU) PIII	Oncology and Supportive Care
Halaven (Non-small cell lung cancer)	AI	(JP/US/EU/AS) PIII	Oncology and Supportive Care
Halaven (Sarcoma)	AI	(US/EU/AS) PIII	Oncology and Supportive Care
Aricept (Lewy body dementia)	AI	(JP) PIII	Neurology
Aricept (Severe Alzheimer's disease)	AI	(CN)PIII	Neurology
Inoveron/BANZEL/E2080 (Pediatric Lennox-Gastaut syndrome)	AI	(US/EU) PIII	Neurology
Aricept (Higher dose 23 mg tablet)	ADA, AF	(JP) PIII	Neurology
E0302 (Amyotrophic lateral sclerosis (ALS))		(JP) PII/III	Neurology
AS-3201 (Diabetic neuropathy)		(US/EU) PII/III	Neurology
Pariet (Prevention of recurrence of gastric and duodenal ulcers during treatment with low-dosage aspirin)	AI	(JP) PII/III	Gastrointestinal and Hepatic Disorders
BAN2401 (Alzheimer's disease)		(US/EU) PII	Neurology
E5501 (Thrombocytopenia in chronic liver disease requiring surgery)		(US) PII	Vascular and Immunological Reaction
E5501 (Thrombocytopenia during interferon therapy (both initiation and maintenance) for hepatitis C)		(US) PII	Vascular and Immunological Reaction
E6005 (Atopic dermatitis)		(JP) PII	Vascular and Immunological Reaction
E6201 (Psoriasis)		(US/EU) PII	Vascular and Immunological Reaction
E7080 (Endometrial cancer)		(US/EU) PII	Oncology and Supportive Care
E7080 (Melanoma)		(US/EU) PII	Oncology and Supportive Care
E7080 (Glioma)		(US) PII	Oncology and Supportive Care

(1) Oncology and Supportive Care

Product Name: **Halaven** Research Code: **E7389** Generic Name:

Research Code: **MORAb-004** (Anticancer agent / humanized anti-endosialin monoclonal antibody)

Description: A humanized IgG1 monoclonal antibody that targets Tumor Endothelial Marker 1 (TEM-1) / endosialin. Expected to exhibit an antitumor effect against carcinomas that express endosialin.

Melanoma	US/EU: PII	Inj.
Colorectal cancer	US/EU: PII	Inj.
Sarcoma	US/EU: PII	Inj.

Research Code: **MORAb-009** Generic Name: **amatuximab** (Anticancer agent / chimeric anti-mesothelin monoclonal antibody)

Description: A chimeric IgG1 monoclonal antibody that blocks the function of mesothelin. Expected to exhibit an antitumor effect against carcinomas that express mesothelin.

Mesothelioma	US/EU: PII	Inj.
--------------	------------	------

Product Name: **Dacogen** Research Code:

Japanese New Drug Application (J-NDA) submission for partial-onset seizures and generalized seizures is planned for FY2014.

Research Code: **AS-3201** Generic Name: **ranirestat** (Treatment for diabetic complications / aldose reductase inhibitor)

Description: An aldose reductase inhibitor that is believed to reduce intracellular accumulation of sorbitol. Currently being investigated as a potential treatment for diabetic neuropathy, one of the most common diabetic complications.

Diabetic neuropathy

US/EU: PII/III

Oral

Product Name: **Zonegran** Research Code: **E2090** Generic Name: **zonisamide** (Antiepileptic agent)

Description: Believed to exhibit a broad antiepileptic spectrum and is well-tolerated. Currently indicated as an adjunctive therapy and monotherapy for the treatment of partial-onset seizures in patients with epilepsy.

Research Code: **E5564** Generic Name: **eritoran** (Treatment for severe sepsis / endotoxin antagonist)

Description: Exhibits endotoxin antagonist effects that inhibit isolation of inflamma

